製品名:3-Chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole

IUPAC Name:3-(4-chloro-1,2,5-thiadiazol-3-yl)pyridine

CAS番号:131986-28-2
分子式:C7H4ClN3S
純度:95%
カタログ番号:CM175538
分子量:197.64

包装単位 有効在庫 価格(USD) 数量
CM175538-100mg in stock ƀư
CM175538-250mg in stock Ǝưǜ
CM175538-1g in stock ưNJǜ
CM175538-5g in stock ƀưǜ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:131986-28-2
分子式:C7H4ClN3S
融点:-
SMILESコード:ClC1=NSN=C1C1=CC=CN=C1
密度:
カタログ番号:CM175538
分子量:197.64
沸点:297.197°C at 760 mmHg
MDL番号:MFCD03066187
保管方法:Store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Thiadiazoles
Thiadiazoles are a subfamily of azoles. Structurally, they are five-membered heterocyclic compounds containing two nitrogen atoms and one sulfur atom, and two double bonds, forming an aromatic ring. Depending on the relative positions of the heteroatoms, there are four possible structures; these forms do not interconvert and are therefore structural isomers rather than tautomers. These compounds themselves are rarely synthesized and have no particular utility, however, compounds that use them as structural motifs are fairly common in pharmacology.

Column Infos

COBENFY
Bristol Myers Squibb announced that the FDA has approved COBENFY® (xanomeline and trospium chloride). COBENFY represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M1 and M4 receptors in the brain without blocking D2 receptors. COBENFY® (xanomeline and trospium chloride), formerly KarXT, is an oral medication for the treatment of schizophrenia in adults. COBENFY combines xanomeline, a dual M1 - and M4 - preferring muscarinic receptor agonist, with trospium chloride, a muscarinic receptor antagonist that does not appreciably cross the blood-brain barrier, primarily acting in peripheral tissues. While the exact mechanism of action of COBENFY is unknown, its efficacy is thought to be due to the agonist activity of xanomeline at M1 and M4 muscarinic acetylcholine receptors in the central nervous system.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.